<DOC>
	<DOCNO>NCT01281228</DOCNO>
	<brief_summary>Glucagon-like peptide 1 ( GLP-1 ) base therapy , exenatide , already successfully employ treatment Type 2 Diabetes ( T2DM ) . Exenatide improve glycemic control associate reduce food intake body weight . The investigator hypothesize affect central reward satiety circuit may contribute weight loss .</brief_summary>
	<brief_title>The Effect GLP-1 Receptor Activation Central Reward Satiety Obesity Diabetes</brief_title>
	<detailed_description>The aim project determine 1 ) whether GLP-1 receptor activation CNS reward satiety circuit occur , context food ( -related ) stimulus ; effect alter obese diabetic compare lean individual 2 ) independent postprandial metabolic hormonal change 3 ) effect GLP-1-receptor-mediated 4 ) CNS change correlate subsequent feeding behaviour . Methods The investigator compare 16 obese T2DM-patients , 16 normoglycemic obese 16 healthy lean individual , respect food ( -related ) neuronal activity central reward satiety circuit blood oxygen level-dependent ( BOLD ) fMRI . fMRI perform intravenous infusion ) GLP-1 receptor agonist exenatide ; b ) exenatide GLP-1 receptor antagonist ( exendin 9-39 ) ( investigate whether exenatide-induced effect GLP-1-receptor mediate ) c ) saline ; randomize order , separate day . To tease concomitant postprandial metabolic hormonal influence , measurement perform somatostatin pancreatic clamp replacement basal insulin , glucagon growth hormone . Finally , correlate change brain activity subsequent feeding behavior , investigator measure food intake , self-reported hunger , satiety mood , choice-buffet scanning . Expected Results This project gain insight ( CNS ) mechanisms underlie observed effect GLP-1 receptor agonist exenatide food intake body weight obese , diabetic healthy lean individual . These finding may increase understand development obesity weight loss problem obese diabetic individual role GLP-1 central regulation feed behavior/appetite control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>For 3 study group : 1. age 1870 year . 2 . Men woman . For woman , postmenopausal woman ( ascertained serum FSH ) include order avoid variation related menstrual cycle . 3 . To promote comparability overcome interference lateralization , righthanded person include . For healthy lean subject , inclusion criterion : 1. bodymass index ( BMI ) &lt; 25 kg/m2 2. stable bodyweight ( &lt; 5 % report change previous 3 month ) 3 . Normal fast 2h postload glucose ascertain 75g oral glucose tolerance test ( OGTT ) For normoglycemic obese individual , inclusion criterion : 1. bodymass index ( BMI ) ≥30 kg/m2 2. stable bodyweight ( &lt; 5 % report change previous 3 month ) 3 . Normal fast 2h postload glucose ascertain 75g oral glucose tolerance test ( OGTT ) For obese T2DM individual , inclusion criterion : 1 . Diagnosed T2DM ( 20 ) &gt; 3 month prior screen 2 . BMI ≥30 kg/m2 3 . HbA1c 6.28.5 % 4 . Treatment metformin stable dose least 3 month . In obese T2DM patient , blood glucose weight lower agent allow within 3 month screen except metformin . The normoglycemic lean obese individual allow take blood glucoselowering agent time study . For individual , exclusion criterion : 1. congestive heart failure ( NYHA IIIV ) 2. chronic renal failure ( glomerular filtration rate &lt; 60 mL/min/1.73m2 per Modification Diet Renal Disease ( MDRD ) ) serious liver impairment 3. history gastrointestinal disorder , include gastroparesis , pancreatitis cholelithiasis 4. neurological illness 5. malignancy 6. pregnancy breast feed 7. implantable device 8. substance abuse 9. addiction 10. contraindication MRI , claustrophobia pacemaker 11. psychiatric illness , include eat disorder depression 12. hypersensitivity active substance excipients 13. chronic use glucocorticoid centrally act drug within 2 week immediately prior screen 14. use cytostatic immunomodulatory agent 15. participation study 16. individual receive treatment within last 30 day drug receive regulatory approval indication time study entry 17. individual investigator site personnel directly affiliate study , immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child , sibling , whether biological legally adopt 18. individual previously complete withdrawn study study investigate GLP1 receptor agonist dipeptidyl peptidase ( DPP ) 4 within 6 month 19. individual , opinion investigator , unsuitable way participate study 20. individual employ Amylin Pharmaceutical Inc. Eli Lilly &amp; company ( , employee , temporary contract worker , designees responsible conduct study ) . Immediate family Amylin Lilly employee may participate sponsor clinical trial , permit participate Amylin Lilly facility . Immediate family define spouse , parent , child , sibling , whether biological legally adopt 21. poor commandment Dutch language ( mental ) disorder precludes full understand purpose , instruction hence participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Exenatide</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Incretin hormone</keyword>
	<keyword>GLP-1 agonist</keyword>
	<keyword>Satiety</keyword>
	<keyword>Reward</keyword>
</DOC>